Albemarle Stock Forecast, Price & News

Albemarle's stock was trading at $70.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALB shares have increased by 157.1% and is now trading at $180.14.
View which stocks have been most impacted by COVID-19.

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albemarle in the last year. There are currently 6 sell ratings, 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Albemarle stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALB, but not buy additional shares or sell existing shares.
View analyst ratings for Albemarle or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Albemarle a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Albemarle wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Albemarle is scheduled to release its next quarterly earnings announcement on Wednesday, February 17th 2021.
View our earnings forecast for Albemarle.

Albemarle will be holding an earnings conference call on Wednesday, February 17th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Albemarle Co. (NYSE:ALB) posted its quarterly earnings results on Monday, November, 9th. The specialty chemicals company reported $1.09 EPS for the quarter, topping the Zacks' consensus estimate of $0.78 by $0.31. The specialty chemicals company had revenue of $746.87 million for the quarter, compared to analyst estimates of $734.75 million. Albemarle had a net margin of 11.77% and a return on equity of 11.96%. The firm's revenue for the quarter was down 15.1% on a year-over-year basis. During the same quarter last year, the business posted $1.53 earnings per share.
View Albemarle's earnings history.

Albemarle declared a quarterly dividend on Tuesday, October 27th. Shareholders of record on Friday, December 11th will be paid a dividend of $0.385 per share on Monday, January 4th. This represents a $1.54 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Thursday, December 10th.
View Albemarle's dividend history.

Albemarle pays an annual dividend of $1.54 per share and currently has a dividend yield of 0.85%. Albemarle has been increasing its dividend for 27 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Albemarle is 25.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Albemarle will have a dividend payout ratio of 38.50% next year. This indicates that Albemarle will be able to sustain or increase its dividend.
View Albemarle's dividend history.

Albemarle issued an update on its FY20 earnings guidance on Wednesday, November, 4th. The company provided earnings per share guidance of $3.80-4.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.48. The company issued revenue guidance of $3.05-3.15 billion, compared to the consensus revenue estimate of $3.04 billion.

23 analysts have issued 12 month target prices for Albemarle's shares. Their forecasts range from $50.00 to $175.00. On average, they anticipate Albemarle's stock price to reach $100.00 in the next year. This suggests that the stock has a possible downside of 44.5%.
View analysts' price targets for Albemarle or view Wall Street analyst' top-rated stocks.

Albemarle saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 4,420,000 shares, a decrease of 30.8% from the December 15th total of 6,390,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 3.6 days.
View Albemarle's Short Interest.

Some companies that are related to Albemarle include The Sherwin-Williams (SHW), Ecolab (ECL), Valaris (VAL), Celanese (CE), International Flavors & Fragrances (IFF), RPM International (RPM), Ashland Global (ASH), Quaker Chemical (KWR), NewMarket (NEU), Balchem (BCPC), PolyOne (POL), W. R. Grace & Co. (GRA), Sensient Technologies (SXT), H.B. Fuller (FUL) and Stepan (SCL).
View all of ALB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albemarle investors own include Intact Financial Co. (IFC.TO) (IFC), Constellation Software Inc. (CSU.TO) (CSU), AutoCanada Inc. (ACQ.TO) (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy Inc. (VET.TO) (VET), Wheaton Precious Metals Corp. (WPM.TO) (WPM), NVIDIA (NVDA), Rogers Communications (RCI) and Alibaba Group (BABA).

Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALB."

Albemarle's stock is owned by many different retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.19%), Axel Capital Management LLC (0.16%), Epiq Partners LLC (0.03%), Crossmark Global Holdings Inc. (0.02%), State of Alaska Department of Revenue (0.02%) and Guild Investment Management Inc. (0.01%). Company insiders that own Albemarle stock include Deeanne J Marlow, Eric Norris, Karen G Narwold, Luther C Iv Kissam, Raphael Goszcz Crawford and Scott Tozier.
View institutional ownership trends for Albemarle.

ALB stock was sold by a variety of institutional investors in the last quarter, including Guild Investment Management Inc., Scout Investments Inc., First Hawaiian Bank, State of Alaska Department of Revenue, Contravisory Investment Management Inc., Fulton Breakefield Broenniman LLC, Red Spruce Capital LLC, and Pinnacle Bank. Company insiders that have sold Albemarle company stock in the last year include Karen G Narwold, Luther C Iv Kissam, Raphael Goszcz Crawford, and Scott Tozier.
View insider buying and selling activity for Albemarle or view top insider-selling stocks.

ALB stock was bought by a variety of institutional investors in the last quarter, including Axel Capital Management LLC, Crossmark Global Holdings Inc., Engrave Wealth Partners LLC, Epiq Partners LLC, Redpoint Investment Management Pty Ltd, Radnor Capital Management LLC, IFM Investors Pty Ltd, and Charles Schwab Trust Co. Company insiders that have bought Albemarle stock in the last two years include Deeanne J Marlow, and Eric Norris.
View insider buying and selling activity for Albemarle or or view top insider-buying stocks.

Shares of ALB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALB stock can currently be purchased for approximately $180.14.

Albemarle has a market capitalization of $19.18 billion and generates $3.59 billion in revenue each year. The specialty chemicals company earns $533.23 million in net income (profit) each year or $6.04 on an earnings per share basis. Albemarle employs 6,000 workers across the globe.

The official website for Albemarle is www.albemarle.com.

Albemarle's mailing address is 4250 CONGRESS STREET SUITE 900, CHARLOTTE NC, 28209. The specialty chemicals company can be reached via phone at 980-299-5700 or via email at [email protected]